EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

A Novel CD58 Mutation–Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients

Hui-Li Wang, Chun-Yu Shang, Wei Hua, Hua Yin, Yue Li, Jun-Heng Liang, Rui Gao, Bi-Hui Pan, Xin-Yu Zhang, Jia-Zhu Wu, Hao-Rui Shen, Li Wang und 3 weitere

Cancer Research and Treatment · 2026

DOI: 10.4143/crt.2024.1143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2026. Verfasst von Hui-Li Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Mutation, CD58 Antigens, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Science and Technology Department, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

CD58, a ligand of the CD2 receptor on T cells and natural killer cells, is abnormally expressed in diffuse large B-cell lymphoma (DLBCL). However, data on the value of CD58 mutation (CD58mut) in DLBCL are limited. Here, we aimed to evaluate the characteristics and prognostic value of CD58mut in DLBCL patients.Materials and Methods The available clinical information and corresponding mutation data of DLBCL were obtained from published articles. Ultimately, 3,025 DLBCL patients in published cohorts were enrolled in the final analysis. Among the 202 DLBCL patients in the Jiangsu Province Hospital (JSPH) cohort, all tumor tissue samples were collected to perform next-generation sequencing and gene expression was analyzed via RNA-seq.

Results

We found that 8.2% (250/3,025) of patients were CD58mut in integrated cohort, whereas 11.4% (23/202) in the JSPH cohort. CD58mut patients exhibit inferior progression-free survival (the integrated cohort: hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.77 to 1.20; p=0.663 the JSPH cohort: HR, 1.85; 95% CI, 0.85 to 4.04; p=0.052) and overall survival (the integrated cohort: HR, 1.43; 95% CI, 1.15 to 1.77; p < 0.001; the JSPH cohort: HR, 2.40; 95% CI, 0.83 to 6.93; p=0.026). A model based on six signature genes (MRO, OXTR, RASL11A, RLN1, SIGLEC1, and PROM2) was constructed via machine learning. To optimize risk stratification and survival prediction for CD58mut patients, biological mechanism of the poorer prognosis in high-risk group may be related to the greater abundance of immunosuppressive cells, especially M2 macrophages.

Conclusion

Our results indicated that CD58mut could serve as a novel prognostic factor for DLBCL patients, and further exploration of personalized treatment strategies for high-risk DLBCL patients based on the risk score model is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseMutationCD58 AntigensBiomarkers, TumorHumansPrognosisFemaleMaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

Biological mechanismCD58 mutationDiffuse large B-cell lymphomaPrognostic modelRisk factors

Substanzen

CD58 AntigensBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Department of Hematology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
  • Nanjing Geneseeq Technology Inc., Nanjing, China.
  • Department of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. liangjinhua1990@126.com.
  • Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. xuwei10000@hotmail.com.

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Science and Technology Department
  • China Postdoctoral Science Foundation
  • Nanjing Municipal Returned Overseas Scholars Foundation
  • Jiangsu Province Hospital Talent Specialized Foundation
  • Jiangsu Province "333" Project
  • Jiangsu Province Hospital Clinical Diagnosis and Treatment Technologies Innovation Project Foundation
  • Jiangsu Province “333” Project

Zitieren

APA

Wang, H. L., Shang, C. Y., Hua, W., Yin, H., Li, Y., Liang, J. H., Gao, R., Pan, B. H., Zhang, X. Y., Wu, J. Z., Shen, H. R., Wang, L., Li, J. Y., Liang, J. H., & Xu, W. (2026). A Novel CD58 Mutation–Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.1143

Vancouver

Wang HL, Shang CY, Hua W, Yin H, Li Y, Liang JH, et al. A Novel CD58 Mutation–Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients. Cancer Research and Treatment. 2026. doi:10.4143/crt.2024.1143

BibTeX
@article{Wang2026,
  author = {Wang, Hui-Li and Shang, Chun-Yu and Hua, Wei and Yin, Hua and Li, Yue and Liang, Jun-Heng and Gao, Rui and Pan, Bi-Hui and Zhang, Xin-Yu and Wu, Jia-Zhu and Shen, Hao-Rui and Wang, Li and Li, Jian-Yong and Liang, Jin-Hua and Xu, Wei},
  title = {A Novel CD58 Mutation–Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients},
  journal = {Cancer Research and Treatment},
  year = {2026},
  doi = {10.4143/crt.2024.1143}
}
Kostenlos starten →